KC-34(SPC-A9)
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →
Ionizable lipid for LNP and nucleic-acid delivery research.
CICL 207 is structurally optimized based on Lipid CICL-1. CICL207 is a constrained ionizable cationic lipid designed for lipid nanoparticle (LNP) delivery systems developed by Capstan. Its structure features a rigid cyclic backbone (e.g., pyrrolidine-derived core) paired with a tertiary amine group that ionizes at acidic pH (pKa ~6.5–7.0), enhancing endosomal escape. The lipid includes asymmetric hydrophobic tails (likely C14–C18 alkyl/ester chains) to stabilize LNP membranes and improve nucleic acid encapsulation. Integrated into LNPs (e.g., 58% CICL-207, 10% DSPC, 30.5% cholesterol, PEG-lipids), it enables targeted delivery to T cells (anti-CD5/CD8 tLNPs) with high transfection efficiency (spleen T cells >70% mCherry+), reduced liver uptake, and low toxicity (no significant ALT/AST elevation in rats). Its constrained design balances stability, tissue specificity, and biocompatibility for gene therapy applications.CICL 207 (F50) significantly outperforms CICL-1 by delivering dramatically enhanced target cell transfection with reduced off-target effects. It achieves >50% transfection efficiency in splenic T-cells—nearly double that of CICL-1—while slashing off-target expression in liver cells to <5% (versus >15% for CICL-1. This precision translates to superior therapeutic outcomes: CICL-207 enables ~95% B-cell depletion in CAR-T applications, far exceeding CICL-1 ’s ~60% efficacy. Critically, it maintains an exceptional safety profile, showing no significant liver toxicity or inflammatory cytokine elevation even at high doses. Furthermore, CICL-207 demonstrates 2-fold higher transfection efficiency in hematopoietic stem cells, enabling robust gene editing. Its optimized pKa (~6.5) and constrained amine structure enhance endosomal escape while minimizing Kupffer cell uptake, making it ideal for targeted therapeutics requiring both potency and safety.
| CAS No. | Not available |
| Chemical Name | CICL-207 |
| Synonyms | CICL207, CICL 207 |
| SMILES | CCCCCCCCC(=O)OCC(COC(=O)CCCCCCC)CC(=O)OC[C@@H]1C[C@@H](OC(=O)CC(COC(=O)CCCCCCCC)COC(=O)CCCCCCCC)CN1C(=O)OCCN(C)C |
| Formula | C56H100N2O14 |
| M.Wt | 1,024.72 |
| Purity | ELSD-HPLC>95% |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | US2025012778A1 |
The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.
Solvent volumes update from the molecular weight above.
| Mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 9.7588 mL | 1.9518 mL | 975.88 μL |
| 25 mg | 24.3969 mL | 4.8794 mL | 2.4397 mL |
| 50 mg | 48.7938 mL | 9.7588 mL | 4.8794 mL |
| 100 mg | 97.5876 mL | 19.5175 mL | 9.7588 mL |
| 250 mg | 243.9691 mL | 48.7938 mL | 24.3969 mL |
Contact our team with the catalog number and requested quantity.